Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRV111 in Oral Squamous Cell Carcinoma
NCT03502148Phase 2Completed
- Sponsor
- Privo Technologies, Inc.
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PRV111 in oral squamous cell carcinoma (OSCC), sponsored by Privo Technologies, Inc. Primary endpoints: Efficacious Dose of PRV111 Via Number of Tumor Responses at 21 days and Safe Dose of PRV111 Via Number of Dose-Limiting Toxicities at 21 days. Started Jun 2018; status: completed.
02
Drugs
PRV111
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT03502148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502148.